---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-020591"
form_type: "8-K"
ticker: "AMIX"
cik: "0001617867"
company_name: "Autonomix Medical, Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:54:24.830887+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Autonomix reports positive preliminary PoC trial results in pancreatic cancer pain patients; 60% responders

## Summary
- 60% of lead-in patients responded with mean 6.33 VAS pain reduction (8.0 to 1.67) at 7 days post-procedure.
- No procedural complications or significant adverse events in the first five patients.
- Responders reported 78% improvement in quality of health and 45% improvement in quality of life at 7 days.
- Femoral access patients responded; brachial access did not; trial enrollment on track for year-end 2024.
- Pain relief as quick as 1 day post-procedure; two patients succumbed to disease (expected, unrelated).

## SEC filing metadata
- accession: 0001437749-24-020591
- form_type: 8-K
- ticker: AMIX
- cik: 0001617867
- company_name: Autonomix Medical, Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617867/000143774924020591/0001437749-24-020591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617867/000143774924020591/amix20240617_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-020591
- JSON: https://secwatch.observer/filing/0001437749-24-020591.json
- Plain text: https://secwatch.observer/filing/0001437749-24-020591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.